American Research Corporation

San Antonio, Texas 78215

3 studies enrolling now · 28 studies all time

What they study most

Advanced Liver Fibrosis, Compensated Cirrhosis, Diabetes Mellitus, Type 2, Healthy Volunteers, Hepatic Impairment, Hepatic Insufficiency, Hepatitis C, Hypertension, Portal, Hypothyroidism, Liver Cirrhosis, Liver Diseases, Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease

Studies at this site

• Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis — Recruiting now
• Pharmacokinetic Study of Vorasidenib in Severe Hepatically Impaired and Matched-Control Participants — Recruiting now
• A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers. — Recruiting now
• Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) — Running, not enrolling
• A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. — Completed
• A Study to Test How BI 1584862 is Taken up in the Blood of People With and Without Liver Problems — Completed
• To Evaluate Safety and Tolerability of the Fixed- Dose Combination of Obeticholic Acid and Bezafibrate — Stopped early
• Prescreening Study to Identify Potential Wilson Disease Participants for Gene-Editing Clinical Trial — Running, not enrolling
• An Open-Label Study Following Oral Dosing of Seladelpar to Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI) — Completed
• A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) — Stopped early
• Study of XP-8121 For the Treatment of Adult Subjects With Hypothyroidism — Completed
• Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH) — Completed
• A Phase 2b Study of Icosabutate in Fatty Liver Disease — Completed
• DZD9008 PK Study in Hepatic Impairment Subjects — Completed
• A Clinical Trial of ALE.F02 in Patients With Advanced Liver Fibrosis and/or With Mild Cirrhosis — Completed
• Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASH — Completed
• A Study to Investigate the Effect of Mild and Moderate Hepatic Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Hepatic Function — Completed
• Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus — Completed
• Pharmacokinetics of Sotorasib in Healthy Participants and Participants With Moderate or Severe Hepatic Impairment — Completed
• A Study of Vorasidenib in Participants With Moderate or Mild Hepatic Impairment and Matched Participants With Normal Hepatic Function — Completed
• Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis — Completed
• Study to Evaluate the Efficacy and Safety of CC-90001 in Participants With Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis — Stopped early
• Leronlimab (PRO 140) in Patients With Nonalcoholic Steatohepatitis — Completed
• Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis — Status unconfirmed
• AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH) — Stopped early
• Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH) — Completed
• Phase III Daclatasvir, Sofosbuvir, and Ribavirin in Cirrhotic Participants and Participants Post-liver Transplant — Completed
• Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCV — Completed